Safety of everolimus with reduced calcineurin inhibitor exposure in de novo kidney transplants: an analysis from the randomized TRANSFORM study
Background. The safety profiles of standard therapy versus everolimus with reduced-exposure calcineurin inhibitor (CNI) therapy using contemporary protocols in de novo kidney transplant recipients have not been compared in detail. Methods. TRANSFORM was a randomized, international trial in which de...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
September 2019
|
| In: |
Transplantation
Year: 2019, Jahrgang: 103, Heft: 9, Pages: 1953-1963 |
| ISSN: | 1534-6080 |
| DOI: | 10.1097/TP.0000000000002626 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1097/TP.0000000000002626 Verlag, lizenzpflichtig, Volltext: https://journals.lww.com/transplantjournal/Fulltext/2019/09000/Safety_of_Everolimus_With_Reduced_Calcineurin.36.aspx 
|
| Verfasserangaben: | Helio Tedesco-Silva, Julio Pascual, Ondrej Viklicky, Nikolina Basic-Jukic, Elisabeth Cassuto, Dean Y. Kim, Josep M. Cruzado, Claudia Sommerer, Mohamed Adel Bakr, Valter D. Garcia, Huynh-Do Uyen, Graeme Russ, Myoung Soo Kim, Dirk Kuypers, Matthias Buchler, Franco Citterio, Maria Pilar Hernandez Gutierrez, Peter Bernhardt, and Steve Chadban, on behalf of the TRANSFORM Investigators |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1695350987 | ||
| 003 | DE-627 | ||
| 005 | 20240405193242.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200421s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/TP.0000000000002626 |2 doi | |
| 035 | |a (DE-627)1695350987 | ||
| 035 | |a (DE-599)KXP1695350987 | ||
| 035 | |a (OCoLC)1341316084 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Tedesco-Silva, Helio |e VerfasserIn |0 (DE-588)1208730371 |0 (DE-627)1695350944 |4 aut | |
| 245 | 1 | 0 | |a Safety of everolimus with reduced calcineurin inhibitor exposure in de novo kidney transplants |b an analysis from the randomized TRANSFORM study |c Helio Tedesco-Silva, Julio Pascual, Ondrej Viklicky, Nikolina Basic-Jukic, Elisabeth Cassuto, Dean Y. Kim, Josep M. Cruzado, Claudia Sommerer, Mohamed Adel Bakr, Valter D. Garcia, Huynh-Do Uyen, Graeme Russ, Myoung Soo Kim, Dirk Kuypers, Matthias Buchler, Franco Citterio, Maria Pilar Hernandez Gutierrez, Peter Bernhardt, and Steve Chadban, on behalf of the TRANSFORM Investigators |
| 264 | 1 | |c September 2019 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 21.04.2020 | ||
| 520 | |a Background. The safety profiles of standard therapy versus everolimus with reduced-exposure calcineurin inhibitor (CNI) therapy using contemporary protocols in de novo kidney transplant recipients have not been compared in detail. Methods. TRANSFORM was a randomized, international trial in which de novo kidney transplant patients were randomized to everolimus with reduced-exposure CNI (N = 1014) or mycophenolic acid (MPA) with standard-exposure CNI (N = 1012), both with induction and corticosteroids. Results. Within the safety population (everolimus 1014, MPA 1012), adverse events with a suspected relation to study drug occurred in 62.9% versus 59.2% of patients given everolimus or MPA, respectively (P = 0.085). Hyperlipidemia, interstitial lung disease, peripheral edema, proteinuria, stomatitis/mouth ulceration, thrombocytopenia, and wound healing complications were more frequent with everolimus, whereas diarrhea, nausea, vomiting, leukopenia, tremor, and insomnia were more frequent in the MPA group. The incidence of viral infections (17.2% versus 29.2%; P < 0.001), cytomegalovirus (CMV) infections (8.1% versus 20.1%; P < 0.001), CMV syndrome (13.6% versus 23.0%, P = 0.044), and BK virus (BKV) infections (4.3% versus 8.0%, P < 0.001) were less frequent with everolimus. CMV infection was less common with everolimus versus MPA after adjusting for prophylaxis therapy in the D+/R− subgroup (P < 0.001). Study drug was discontinued more frequently due to rejection or impaired healing with everolimus, and more often due to BKV infection or BKV nephropathy with MPA. - Conclusions. De novo everolimus with reduced-exposure CNI yielded a comparable incidence, though a distinctly different pattern, of adverse events versus current standard of care. Both regimens are safe and effective, yet their distinct profiles may enable tailoring for individual kidney transplant recipients. | ||
| 700 | 1 | |a Pascual, Julio |e VerfasserIn |4 aut | |
| 700 | 1 | |a Viklicky, Ondrej |e VerfasserIn |4 aut | |
| 700 | 1 | |a Basic-Jukic, Nikolina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cassuto, Elisabeth |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kim, Dean Y. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cruzado, Josep M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sommerer, Claudia |d 1971- |e VerfasserIn |0 (DE-588)121857654 |0 (DE-627)705680002 |0 (DE-576)292921829 |4 aut | |
| 700 | 1 | |a Adel Bakr, Mohamed |e VerfasserIn |4 aut | |
| 700 | 1 | |a Garcia, Valter D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Uyen, Huynh-Do |e VerfasserIn |4 aut | |
| 700 | 1 | |a Russ, Graeme |e VerfasserIn |4 aut | |
| 700 | 1 | |a Soo Kim, Myoung |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kuypers, Dirk |e VerfasserIn |4 aut | |
| 700 | 1 | |a Buchler, Matthias |e VerfasserIn |4 aut | |
| 700 | 1 | |a Citterio, Franco |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hernandez Gutierrez, Maria Pilar |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bernhardt, Peter |e VerfasserIn |4 aut | |
| 700 | 1 | |a Chadban, Steve |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Transplantation |d Hagerstown, Md. : Lippincott Williams & Wilkins, 1963 |g 103(2019), 9, Seite 1953-1963 |h Online-Ressource |w (DE-627)32529738X |w (DE-600)2035395-9 |w (DE-576)097188794 |x 1534-6080 |7 nnas |a Safety of everolimus with reduced calcineurin inhibitor exposure in de novo kidney transplants an analysis from the randomized TRANSFORM study |
| 773 | 1 | 8 | |g volume:103 |g year:2019 |g number:9 |g pages:1953-1963 |g extent:11 |a Safety of everolimus with reduced calcineurin inhibitor exposure in de novo kidney transplants an analysis from the randomized TRANSFORM study |
| 856 | 4 | 0 | |u https://doi.org/10.1097/TP.0000000000002626 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://journals.lww.com/transplantjournal/Fulltext/2019/09000/Safety_of_Everolimus_With_Reduced_Calcineurin.36.aspx |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200421 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 121857654 |a Sommerer, Claudia |m 121857654:Sommerer, Claudia |d 50000 |e 50000PS121857654 |k 0/50000/ |p 8 | ||
| 999 | |a KXP-PPN1695350987 |e 362792293X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"recId":"1695350987","name":{"displayForm":["Helio Tedesco-Silva, Julio Pascual, Ondrej Viklicky, Nikolina Basic-Jukic, Elisabeth Cassuto, Dean Y. Kim, Josep M. Cruzado, Claudia Sommerer, Mohamed Adel Bakr, Valter D. Garcia, Huynh-Do Uyen, Graeme Russ, Myoung Soo Kim, Dirk Kuypers, Matthias Buchler, Franco Citterio, Maria Pilar Hernandez Gutierrez, Peter Bernhardt, and Steve Chadban, on behalf of the TRANSFORM Investigators"]},"physDesc":[{"extent":"11 S."}],"relHost":[{"part":{"pages":"1953-1963","text":"103(2019), 9, Seite 1953-1963","year":"2019","volume":"103","extent":"11","issue":"9"},"note":["Gesehen am 11.06.2019"],"origin":[{"dateIssuedKey":"1963","publisher":"Lippincott Williams & Wilkins ; Ovid","publisherPlace":"Hagerstown, Md. ; [Erscheinungsort nicht ermittelbar]","dateIssuedDisp":"1963-"}],"title":[{"title":"Transplantation","subtitle":"the official journal of the Transplantation Society","title_sort":"Transplantation"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"disp":"Safety of everolimus with reduced calcineurin inhibitor exposure in de novo kidney transplants an analysis from the randomized TRANSFORM studyTransplantation","corporate":[{"role":"isb","display":"Transplantation Society"}],"id":{"eki":["32529738X"],"issn":["1534-6080"],"zdb":["2035395-9"]},"physDesc":[{"extent":"Online-Ressource"}],"recId":"32529738X","pubHistory":["1.1963 -"]}],"id":{"eki":["1695350987"],"doi":["10.1097/TP.0000000000002626"]},"person":[{"display":"Tedesco-Silva, Helio","family":"Tedesco-Silva","given":"Helio","role":"aut"},{"role":"aut","given":"Julio","display":"Pascual, Julio","family":"Pascual"},{"family":"Viklicky","display":"Viklicky, Ondrej","role":"aut","given":"Ondrej"},{"family":"Basic-Jukic","display":"Basic-Jukic, Nikolina","given":"Nikolina","role":"aut"},{"role":"aut","given":"Elisabeth","display":"Cassuto, Elisabeth","family":"Cassuto"},{"given":"Dean Y.","role":"aut","display":"Kim, Dean Y.","family":"Kim"},{"role":"aut","given":"Josep M.","family":"Cruzado","display":"Cruzado, Josep M."},{"role":"aut","given":"Claudia","display":"Sommerer, Claudia","family":"Sommerer"},{"display":"Adel Bakr, Mohamed","family":"Adel Bakr","role":"aut","given":"Mohamed"},{"given":"Valter D.","role":"aut","family":"Garcia","display":"Garcia, Valter D."},{"role":"aut","given":"Huynh-Do","display":"Uyen, Huynh-Do","family":"Uyen"},{"role":"aut","given":"Graeme","display":"Russ, Graeme","family":"Russ"},{"role":"aut","given":"Myoung","family":"Soo Kim","display":"Soo Kim, Myoung"},{"role":"aut","given":"Dirk","family":"Kuypers","display":"Kuypers, Dirk"},{"display":"Buchler, Matthias","family":"Buchler","given":"Matthias","role":"aut"},{"given":"Franco","role":"aut","family":"Citterio","display":"Citterio, Franco"},{"given":"Maria Pilar","role":"aut","display":"Hernandez Gutierrez, Maria Pilar","family":"Hernandez Gutierrez"},{"family":"Bernhardt","display":"Bernhardt, Peter","role":"aut","given":"Peter"},{"display":"Chadban, Steve","family":"Chadban","given":"Steve","role":"aut"}],"language":["eng"],"note":["Gesehen am 21.04.2020"],"origin":[{"dateIssuedKey":"2019","dateIssuedDisp":"September 2019"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title":"Safety of everolimus with reduced calcineurin inhibitor exposure in de novo kidney transplants","title_sort":"Safety of everolimus with reduced calcineurin inhibitor exposure in de novo kidney transplants","subtitle":"an analysis from the randomized TRANSFORM study"}]} | ||
| SRT | |a TEDESCOSILSAFETYOFEV2019 | ||